Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - gemtsitabiin - infusioonilahuse pulber - 38mg 1ml 2000mg 1tk; 38mg 1ml 1500mg 1tk; 38mg 1ml 200mg 1tk

Eesti - eesti - Ravimiamet

alvogen ipco s.a.r.l. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 100mg 1tk

Eesti - eesti - Ravimiamet

bpl bioproducts laboratory gmbh - immunoglobuliin, intravaskulaarseks kasutamiseks - infusioonilahus - 100mg 1ml 100ml 1tk; 100mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - raud(iii)hüdroksiid-polümaltooskompleks - siirup - 10mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

alvogen ipco s.a.r.l. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 1000mg 1tk

Eesti - eesti - Ravimiamet

fresenius kabi oncology plc - gemtsitabiin - infusioonilahuse kontsentraat - 40mg 1ml 50ml 1tk; 40mg 1ml 25ml 1tk; 40mg 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

zentiva k.s. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - raud(iii)hüdroksiid-polümaltooskompleks - närimistablett - 100mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - hüdroksükarbamiid - aneemia, sickle cell - antineoplastilised ained - ennetamine vaso-occlusive tüsistused sirprakuline patsientidel, üle 2-aastased.